Adial Pharmaceuticals, Inc.
Cash Flow Statement
| Line Item | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-2.5M | $-6.5M | $-1.9M | $-1.4M | $1.1M | $-2.9M | $-2.9M | $-3.1M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | $141 | $141 | $141 | $141 | $141 | $141 | $141 | $141 |
| Stock-Based Compensation | $202.4K | $226.0K | $280.8K | $268.4K | $737.6K | $459.6K | $734.1K | $557.0K |
| Net Cash from Operating Activities | $-2.1M | $-1.6M | $-1.2M | $-1.4M | $-1.9M | $-2.3M | $-1.8M | $-3.4M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | — | — | — | — | — |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | — | — | — | — | — | — | — |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $411.1K | $3.8M | $3.4M | $138.7K | $58 | $609.6K | $0 | $0 |
| Net Change in Cash | — | — | — | — | — | — | — | — |
| Free Cash Flow | — | — | — | — | — | — | — | — |